InvestSMART

Starpharma Holdings Limited (ASX: SPL) - Announcements

Current share price for SPL : $0.800 0.015 (1.84%)+

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$382 VivaGel BV granted QIDP and Fast Track designation by US FDA 12 Jan 2017 9:19AM $0.735 $0.800 risen by 8.84%
$382 Starpharma receives $3.5M R&D tax incentive refund 22 Dec 2016 9:25AM $0.685 $0.800 risen by 16.79%
$382 Change in Director's Interest Notice - J Fairley 5 Dec 2016 4:33PM $0.740 $0.800 risen by 8.11%
$382 Appendix 3B 5 Dec 2016 4:32PM $0.740 $0.800 risen by 8.11%
$382 Change in Director's Interest Notice - R Thomas 5 Dec 2016 2:57PM $0.735 $0.800 risen by 8.84%
$382 2016 AGM Results 29 Nov 2016 5:16PM $0.670 $0.800 risen by 19.40%
$382 AGM - Chairman address and CEO presentation 29 Nov 2016 2:05PM $0.668 $0.800 risen by 19.85%
$382 Starpharma signs license for VivaGel Condom in Iran 28 Nov 2016 9:18AM $0.670 $0.800 risen by 19.40%
$382 Starpharma to present at Bio-Europe conference 8 Nov 2016 2:21PM $0.733 $0.800 risen by 9.22%
$382 Appendix 4C - Quarterly Cashflow Report 28 Oct 2016 1:41PM $0.725 $0.800 risen by 10.34%
$382 Additional Priostar Glyphosate Patent Allowed in US 28 Oct 2016 9:34AM $0.705 $0.800 risen by 13.48%
$382 Notice of Annual General Meeting/Proxy Form 26 Oct 2016 10:08AM $0.655 $0.800 risen by 22.14%
$382 Starpharma to present at US Drug Delivery Conference 26 Oct 2016 12:00AM $0.660 $0.800 risen by 21.21%
$382 Starpharma to present at ASX Spotlight in Asia 25 Oct 2016 9:40AM $0.645 $0.800 risen by 24.03%
$382 Change in Director's Interest Notice - R Thomas 17 Oct 2016 4:18PM $0.605 $0.800 risen by 32.23%
$382 Change in Director's Interest Notice - J Fairley 13 Oct 2016 4:01PM $0.615 $0.800 risen by 30.08%
$382 Appendix 3B 13 Oct 2016 4:00PM $0.615 $0.800 risen by 30.08%
$382 Enrolment complete for Phase 3 VivaGel BV-R program 13 Oct 2016 10:11AM $0.610 $0.800 risen by 31.15%
$382 Change in Director's Interest Notice - J Fairley 7 Oct 2016 11:44AM $0.630 $0.800 risen by 26.98%
$382 Appendix 3B 7 Oct 2016 11:43AM $0.630 $0.800 risen by 26.98%
$382 Notification of AGM date 3 Oct 2016 9:47AM $0.650 $0.800 risen by 23.08%
$382 Change in Director's Interest Notice - R Thomas 19 Sep 2016 9:08AM $0.660 $0.800 risen by 21.21%
$382 Change in substantial holding 14 Sep 2016 5:24PM $0.680 $0.800 risen by 17.65%
$382 VivaGel condom receives regulatory approval in Canada 13 Sep 2016 9:56AM $0.660 $0.800 risen by 21.21%
$382 Appendix 4E - Correction to NTA Backing 31 Aug 2016 2:23PM $0.705 $0.800 risen by 13.48%

576 - 600 of 888 results

Page 24 of 36

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.